跳至主要内容
临床试验/NCT01595295
NCT01595295已完成不适用

Registry on Hypomethylating Agents in Myeloid Neoplasms, Including Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)

Arbeitsgemeinschaft medikamentoese Tumortherapie20 个研究点 分布在 2 个国家目标入组 1,500 人开始时间: 2009年2月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,500
试验地点
20
主要终点
Response evaluation

研究概览

简要总结

This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially other participating countries. This registry will collect data in a retrospective as well as in a prospective manner at various sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a routine clinical setting in patients with various comorbidities.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with MDS, CMML, and AML
  • who begin with or already have received treatment with with a hypomethylating agent
  • who are willing to provide informed consent

排除标准

  • Due to the non-interventional design of this program there are no specific exclusion criteria.

结局指标

主要结局

Response evaluation

时间窗: up to 10 years

hematological response, marrow response, cytogenetic response (if data is available), quantification of reduced need for transfusions, median response duration

Overall survival

时间窗: up to 10 years

次要结局

  • Documentation of adverse events and toxicities(up to 10 years)
  • Number of treatment cycles(up to 10 years)
  • Number and reasons of dose reductions(up to 10 years)
  • Uni/multivariate analysis of various factors known or thought to influence overall survival in order to establish prognostic markers(up to 10 years)

研究者

发起方
Arbeitsgemeinschaft medikamentoese Tumortherapie
申办方类型
Other
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验